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The need for tissue and organ replacements cannot be satisfied by autograft and 
allografts alone. The purpose of this study was to investigate the feasibility of 
electrospinning a blend of polydioxanone and fibrinogen to produce an engineered tissue 
scaffold. Fiber diameter and pore size of blends were characterized, as well as mechanical 
strength. Cell proliferation assays for 1 and 7 day cultures were preformed, and a 
histological evaluation was performed to determine how favorable the various blends were 
to cell infiltration and proliferation. Some ratios of blends were identified that contained 
viii 
both acceptable mechanical properties and properties that facilitated cell infiltration. These 
findings pave the way for future refinement and use of these scaffolds for a variety of 
tissue engineered targets. 
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Introduction 
 
Background  
 
Biomedical engineering represents the convergence of multiple disciplines of 
science. This convergence of disciplines allows  complex issues in health care to be 
addressed. One rapidly expanding area of biomedical research is tissue engineering. Tissue 
engineering aims to replace and repair damaged or diseased tissues and organs. The 
demand for replacement organs is daunting. It is estimated that treatment for patients with 
organ failure exceeds $400 billion dollars a year [1].  While the nation’s organ transplant 
centers are able to supply some allographic tissue and organs, the demand and waitlist for 
these organs is increasing [2].  Tissue engineering research offers promise to alleviate this 
demand for allographic tissue. Research into replacing organs is ongoing.  Despite 
successes in the field such as dermal tissue engineering [3], many other organ systems are 
awaiting a successful replacement. One such system that would greatly benefit from the 
advent of non-autologous, off the shelf tissue is the urinary system.  
Urinary System Overview 
 
The urinary system plays a vital role in the body. In addition to its obvious function 
in the removal of metabolites via excretion, it plays a pivotal role maintaining homeostasis. 
The urinary system is responsible for maintenance of salts, acids and bases, and secretion 
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of hormones.  The urinary system is composed of four major components; the kidney, the 
ureters, the bladder, and the urethra. 
 Removal of nitrogen is an important function of the kidneys. Amino acid 
catabolism occurs in the liver. Nitrogen from amino acids is converted to urea, and enters 
the blood stream. Urea is then removed from the blood by the kidneys. The kidneys also 
aid in maintaining the balance of important ions including potassium, bicarbonate, calcium 
ions, as well as function in the regulation of blood pH through a process of absorption and 
secretion. The filtrate filtered by each kidney is then passed  to the ureters, which serve to 
deliver urine to the bladder. Delivery is aided by peristalsis.  Ureters consist of the inner 
mucosal layer, followed by a layer of smooth muscle cells. The urethra connects the 
bladder to the exterior of the body, allowing urine to be excreted [4]. 
 The integrity of the urethral and urethral conduits are vital for the preservation of 
renal function, and thus homeostasis. Typically, surgical procedures involving 
reconstruction of the ureter arise from urinary tract obstructions, carcinoma, or trauma 
sustained from injury. Left untreated, these maladies can give rise to symptoms ranging 
from patient discomfort, to renal failure and death. Likewise, problems with the urethra can 
also negatively impact quality of life. Urethra corrected with reconstruction include 
hypodispias, stricture, and tumor growth. Treatments for these diseases have inherent 
problems, and more solutions should be pursued in order to further patient care.   
Urinary Tract Disorders 
Urinary tract obstruction (UTO) is one of several disorders associated with the 
urinary tract. It has also been reported that 166 out of 100,000 hospital visits in the United 
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States were a result of UTO [5]. Clinical presentation of the disease depends on the 
severity of the obstruction. If a single ureter is obstructed (unilateral obstruction), a patient 
may present with dull flanking pain, but might also be asymptomatic. Bilateral obstruction 
however, is accompanied by either lower abdominal or back pain, and may progressively 
show symptoms of renal failure.  In such cases, the renal pelvis becomes dilated and 
enlargement of the kidney occurs resulting in hydronephrosis.   
In a series of over 32,000 autopsies, it was found that 3.8% had hydronephrosis, 
dilation of the renal pelvis due to UTO [5]. Typically hydronephrosis is associated with 
atrophy of the renal parenchyma. Three mechanisms associated with hydronephrosis lead 
to renal failure: pressure atrophy, intrarenal reflux, and ischemia. Pressure atrophy is 
associated with an increased pressure in the renal pelvis. Pressure results in the atrophy of 
the renal medulla leading to renal failure.  In this case, renal papillae are distorted, leading 
to decreased sodium, potassium, and water handling in the distal tubular and collecting 
ducts. Intrarenal reflux occurs when urine moves retrograde to the kidneys. It results in 
cortical and medullary atrophy. Ischemia is associated with the obstruction and occlusion 
of local vasculature around the renal pelvis associated with enlargement of the renal pelvis. 
It is this decrease in blood flow that ultimately leads to ischemic atrophy in the kidney.  
Hydronephrosis is of great concern when dealing with UTO due to these three mechanisms 
leading to organ failure.  The  disease is treated surgically with an ileal conduit, although 
complications do occur [6, 7]. 
Hypertension is also a complication associated with UTO. Resulting fluid retention 
due to UTO causes extracellular matrix expansion. Renin is a soluble plasma enzyme 
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responsible for elevating blood pressure by activating angiotensin. Elevated renin levels 
are associated with UTO, and explain hypertension. It has been observed however that 
removal of the obstruction helps to rectify elevated renin and diminishes hypertension [8]. 
 Tumors  can also induce obstruction and stricture of both the ureter and urethra. 
Transitional cell epithelium lines the lumen of the urinary tract. Roughly 90% of 
carcinomas develop in the bladder and the proximal two thirds of the urethra. Tumors in 
the ureter account for only 2% of carcinomas in the UT. Tumors of the urinary tract are 
polychronotropic, meaning, that they can reappear over both time and space.   In fact, an 
estimated 50%- 70 % of patients with a tumor located in the mucosa will have a 
recurrence.  Typical management for urinary tract tumor is resection. Recurring tumors 
require additional resection, decreasing the amount of urinary tract tissue [9]. 
Proper recognition and treatment of UTO is clearly important. Although proper 
treatments include placement of a bladder catheter, nephrostomy, pyelostomy, cutaneous 
ureterostomy, suprapubic cystostomy, or ileal conduit; each is accompanied by risks of 
recurrent obstruction, ascending urinary tract infection, electrolyte abnormalities, volume 
depletion, and formation of renal calculi. Although these treatments are effective in some 
cases, better treatments should be pursued.  
Urethral defects and maladies negatively impact the quality of life of many 
patients. Two problems of the urethra are hypospadias and urethral strictures. Hypospadias 
is a congenital defect where there is incomplete development of the urethra. The urethral 
opening subsequently appears anywhere on the ventral side of the penis, the scrotum, or 
perineum.  Upwards of 1 in 150 births are diagnosed with hypospadias [10]. Typically, 
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early surgery is used to correct this defect [11]. In severe cases, autologous tissue from 
nonpenile skin, bladder, or buccal mucosa is used to repair urethral defects [12]. 
 Urethral strictures are typically caused by traumatic injury and inflammation. 
Patients with strictures typically present with trouble voiding. Although treatment such as 
stents are a nonsurgical option [13], reconstructive surgery is employed for more severe 
cases.  Grafts from other donor sites, such as penile skin [14],  small intestine submucosa 
[15], and buccal mucosa [16], can also be used for the more complex repairs. Despite 
continually advancing surgical procedures, the instance of complications for repair is 30% 
[10]. 
 In regards to the ureters, obstruction can manifest itself through a range of 
symptoms, from patient discomfort to renal failure. Obstruction of the ureter due to 
strictures has been treated in the past surgically with varying degrees of success. Typically, 
problems arise when patients have a pre-existing condition with colonic or ileum tissue, or 
via metabolic problems incurred by removal of gastrointestinal tract [17, 18]. Metabolic 
acidosis, vitamin B-12 deficiency, and chologenic diarrhea have all been noted as problems 
associated with the use of colonic segments as a ureter substitute [19]. In general, use of a 
tissue autograft  in urinary tract reconstruction is associated with inadequate 
biocompatibility, lack of peristaltic activity, and build up of salt deposits [1]. In addition, 
an autograft  may cause prolonged surgical time, extended hospitalization, and an increase 
in morbidity. [20]   
 Although bowel segments have been shown effective in some cases, new 
alternatives are actively being pursued. One recent alternative is a self expanding, 
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intraluminal metallic stent. [21] These stents have shown to be effective in some animal 
models, but also have inherent problems. Problems with these stents include 
hydroureteronephrosis, severe urothelial hyperplasia, stent migration, stone formation, and 
infection. Recent stent enhancements include lining metal stents with polycarbonate [22].   
These stents were shown to reduce hydroureteronephrosis in a canine model, but were still 
not a total solution to obstruction.  
 Urological disorders are both problematic to treat and degrade quality of life. As 
described above, multiple UT maladies are treated by surgical intervention. Tissue 
engineering presents itself as a promising field in the treatment of urological disorders. 
Native local urological tissue is often the source of tissue for reconstruction, but often this 
option is not feasible. Investigation into novel materials and techniques has been suggested 
for developing materials that can be used as a substitute for natural tissue. 
 
Review of Engineered Urological Tissue 
Natural materials have been considered for engineered urological tissues. Acellular 
collagen matrix obtained from porcine bladders was investigated as a urethral replacement. 
In an early study, an acellular tubular collagen sponge proved successful in regenerating 
uro-epithelail cells along the  inner wall when implanted in dogs. These scaffolds 
importantly did not illicit hydronephrosis [23]. Further studies with collagen sponges 
showed that these scaffolds were seen to preserve urethra morphology, promote migration 
of host cells, and induce angiogenesis into the graft itself [20].  It was later noted that 
uroepithelial cells cultured on meshes of poly(glycolic acid) and implanted into rats and 
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rabbits formed multiple layers of cell lining [24].  Despite this initial success in 
experiments involving ureters, more recent studies in a canine model did not prove as 
promising [25].  Despite the current attempts at  engineered materials, there is no tissue 
engineered effective treatment for urological strictures of the ureter.  
Tissue Engineering 
Many routes of tissue fabrication have been pursued. Some have proven effective, 
other methods have not. Fundamentally, tissue engineering involves deposition of cells 
onto a scaffold, or matrix. Much consideration has been given to the ideal scaffold.  
Macroscopic properties such as strength and modulus can affect the usefulness of the 
scaffold just as much as microscopic properties such pore size and fiber diameter. 
Bioactivity, environments which promote cell attachment and proliferation is also 
paramount [26]. The past several decades has seen many materials used, however none has 
proven totally effective in matching tissue specific matrices [27]. 
Tissue engineering is a rapidly expanding, dynamic field of study. Specifically, 
tissue engineering strives to develop novel replacements for biological tissue. Cells, 
extracellular matrix (ECM), and signaling systems are all vital for a functioning tissue. Our 
laboratory is concerned with recreating ECM with both natural and synthetic proteins. In 
tissues, the ECM contains collagen, glycosaminoglycans, hyaluronic acid, proteoglycans, 
and elastins. In addition to these constituents, enzymes that degrade the matrix and their 
inhibitors are present, allowing for dynamic remodeling of the ECM [28]. 
Cells interact with the ECM via specialized cell receptors. Integrins, 
transmembrane proteins composed of heterodimeric α and β subunits, play a vital role in  
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interactions between the cell and extracellular matrix. Upon binding a ligand, integrins 
illicit a response through the cytoskeleton and cytoplasmic kinases [29]. Signaling 
cascades can modify many cellular characteristics such as morphology, proliferation, and 
genetic regulation.  
Typical engineered scaffolds are made of either natural polymer or synthetic 
polymer. Poly(glycolic acid) (PGA), poly(lactic acid) (PLA) and polycaprolactone (PCL) 
have all seen extensive use in tissue engineering. [1]  Natural polymers use has included 
collagen , elastin, fibrinogen, hemoglobin, and myoglobin.  
In addition to material, scaffold architecture is an important consideration for tissue 
engineering. Fiber size should be around 50 to 500nm in diameter to mimic the ECM [30]. 
Pore size is an important characteristic of scaffolds. Macropores (>50nm , <300um) 
facilitate cell and tissue penetration where micropores (<2nm) and mesopores (>2nm , 
<50nm) allow for solute diffusion [31]. A study comparing cell infiltration into separate 
scaffolds containing electrospun type I collagen and gelatin respectively indicated lack of 
infiltration into gelatin, yet infiltration into collagen matrices. It was suggested that the 
smaller average pore size of gelatin (1500-4000 nm2) precluded cell infiltration, while the 
pore size of collagen (2000-6000 nm2) facilitated cell infiltration [32].  
Electrospinning 
Electrospinning of materials is one method by which the structure of the ECM can 
be reproduced.  Although electrospinning is not a new technique, its applications to 
biomedical engineering are obvious.  The physical basis of electrospinning revolves 
around two main principles, separation of charge and surface tension.  In the 1880s, Lord 
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Rayleigh began investigating the properties that distort a water droplet. He noticed that as 
the electrical potential of the water droplet is increased, the droplet will begin to deform. 
Rayliegh determined that the stabilizing force, surface tension (T) was related to the charge 
Q by spherical radius a.  
T > Q2 / 16πa3                                                                
An increasing charge will ultimately overcome the surface tension of the droplet, at which 
point liquid is thrown off in fine jets [33] . 
 A typical electrospinning setup is shown below. As the syringe (polymer reservoir) 
is depressed, a droplet of liquid forms on the tip of the syringe. This droplet is exposed to 
an electric field applied by a high voltage power supply. As the surface tension is 
overcome by the electrical field, liquid jets are accelerated towards an area of lower 
potential. Typically this area of lower potential is a grounded collection target.   
 
 
Figure 1. A schematic representation of an electrospinning setup. A high voltage power 
supply, solution reservoir, and grounded target are the major components of such a setup.  
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Although this system does not seem complex, many variables can be altered yielding with 
dramatically different results. Altering the potential, polymer, polymer concentration, 
solvent, and mandrel distance to target all yield dramatically different results [34, 35]. In 
addition, mechanical manipulation of the target can dramatically change the way in which 
the fiber is collected. By varying the parameters above, radically different results can be 
achieved. By finding the right combination of variables, a more viable tissue scaffold can 
be forged. 
 
Polydioxanone 
Polydioxanone (PDO) is a polymer that  has been used extensively in biomedical 
applications, specifically in use as sutures.  PDO is produced by ring opening of p-
dioxanone monomers to form polydioxanone polymer.  This process requires heat, and an 
organometallic catalyst such as zirconium acetylacetone, diethylzinc, or zinc L-lactate 
(ZnLac2) , and forms ether-ester bonds [36]. Low temperature however, should be used in 
order to prevent depolymerization to p-dioxanone during polymerization.  
 
 
Figure 2:  Polymerization of p-dioanone to polydioxanone [37].  
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PDO is typically extruded as a monofilament for suture use. The ether group along 
the backbone of PDO allows for its large degree of flexibility. PDO is biodegradable, but 
its degradation rate is much slower than other monofibers [38].  In addition, PDO exhibits 
a low inflammatory response compared to other polymers used in sutures [39]. Despite its 
potential benefits for use as a suture material, PDO has shape memory, which is a major 
drawback in use of sutures. While shape memory is a drawback for PDO in suture use, it 
may prove useful in maintaining structure of a tissue scaffold.  
Although it has had limited use in other biomedical areas [40, 41], it has recently 
been proposed as an ideal material for tissue engineering. In fact, recent studies have 
suggested electrospun PDO might provide an ideal construct for a tissue scaffold [37]. 
Polydioxanone has a proven track record. Its use as a suture material has shown that it is 
biocompatible, and will illicit only a mild immune response. Further, PDO degrades by 
hydrolysis. Presumably, if used as a component of a tissue scaffold, PDO degradation 
might allow further cell infiltration and remodeling of the scaffold.  It has been shown to 
be electrospun, producing fibers in the micron and submicron diameter. Such 
characteristics make it a suitable candidate for scaffold material.  
 
Fibrinogen  
Fibrinogen is a vital plasma protein involved in the coagulation cascade and wound 
healing. Fibrinogen is composed of six chains, chains two α, two β, and two γ chains linked 
by 29 disulfide bonds [42]. Vascular injury initiates a cascade that converts fibrinogen to 
fibrin via thrombin, a serine protease. The N terminal of fibrinogen alpha and beta chains 
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are cleaved, removing glutamate and aspartate residues. Negatively charged glutamate and 
aspartate residues prevent fibrinogen from aggregating until cleavage occurs. Upon 
cleavage, fibrin self assembles and forms fibrous clots, natural scaffolds where platelet 
aggregation occurs.  
 
Figure 3: The structure of fibrinogen. [42] 
Upon injury to a blood vessel, collagen and  subendothelial matrix-bound vWF are 
exposed. Platelets, non-nucleated cells that assist in occluding vascular injuries, contain 
glycoproteins on their plasma membranes that have affinity for collagen  and  
subendothelial matrix-bound vWF. In particular, collagen binding to GPIa glycoprotein on 
platelets causes morphological changes in platelets. These morphological changes induce 
platelets to become spherical, extend pseudopods, and increase platelet-platelet 
interactions. In addition, GPIa binding causes conformational changes to occur in 
GPIIb/IIIa, glycoproteins on the platelet plasma membrane.  This glycoprotein binds vWF 
and fibrinogen. As platelets aggregate, they degranualize. An important component of the 
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platelet granules is adenosine diphosphate (ADP). ADP causes conformational changes 
which allow for increased GPIIb/IIIa binding.  
 Two thrombin activating pathways exist, the intrinsic and extrinsic pathway. The 
extrinsic pathway is initiated by external stimuli such as blunt trauma, while the instrinic 
pathway is initiated by internal stimuli. Both stimuli activate proteases that ultimately 
activate thrombin. Sequential activation of the cascade allows for amplification of the 
signal. Factor XIII is activated during the clotting cascade, this factor serves to crosslink 
glutamine and lysine residues on fibrin [43, 44]. 
 
Figure 4: Illustration of the coagulation cascades catalyzing the formation of cross linked 
fibrin polymers from fibrinogen [45]. 
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Fibrin serves as a natural scaffold in the event of traumatic injuries. Fibrin’s 
inherent bioactivity allows it to act as a surrogate scaffold after it is assembled into a clot.  
Two characteristics allow fibrin to achieve its goal. First, the polymerization forms a clot, 
giving a physical framework, or scaffold for the invasion and proliferation of cells. 
Second, fibrin contains bioactive domains that allow the attraction of cells. These domains 
include integrin binding domains which are attachment points for cells.  
Both the structural characteristics and domains that signal cells allow fibrin to be 
bioactive. It is vital that the scaffolds contain these bioactive domains, but also that the 
scaffolds themselves do not impede migration of cells to these domains. After conversion 
of fibrinogen to fibrin, exposure of receptor binding sites elicit specific fibrin dependant 
cell responses.  
Bioactivity of Fibrinogen 
One way in which cells interact in their environment is integrin receptors. Integrins 
are an integral membrane protein that spans the plasma membrane. Integin is responsible 
for binding to ligands on either other cells or the extracellular matrix. Fibrinogen and fibrin 
contains three integrin binding sites. These binding sites, or ligands, include  two RGD 
sequences on the alpha chain (RGDS α572+/-575 and RGDF α95+/-98) and a non RGD 
sequence on the gamma chain (carboxy terminal γ400+/-411) [42]. These sequences are 
made up of arginine, glycine, and aspartic acid amino acids.   Both fibrinogen and fibrin 
also act through non-integrin receptors [46]. Fibrin can act through ICAM-1 (Intercellular 
Cell Adhesion Molecule) dependant pathways, promoting intercellular adhesion by acting 
as a bridge.  
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 Fibrin and fibrinogen cleavage products also act as mitogens, inducing mitosis in 
endothelial cells, fibroblasts, mesotheilial cells, smooth muscle cells and lymphocytes. 
Fibrinopeptide B cleaveage and the exposure of the amino terminus of the fibrin β chain 
enhance fibroblast and endothelial cell proliferation. This has been a suggested pathway 
for the enhanced proliferation of fibroblasts and endotheial cells in response to injury [47]. 
Intact fibrinogen is mitogenic for lymphoid cells and hemopoietic progenitors. The 
mitogenic effect here is mediated by two non-integrin binding sites, a 92+/-94 kDA 
mitogenic fibrinogen receptor (MFR) and  a ICAM-1 site. Downregulation of MFR may 
explain why normal cells do not proliferate in the circulation [48]. Fibropeptide fragments 
α and β, in addition to fibrinogen products produced during cleavage by thrombin have 
been shown to have proliferatory effects on fibroblasts [49].  
 Fibrin matrices also elicit migratory effects on certain cells including endothelial 
cells, fibroblasts, macrophages, smooth muscle cells, keratinocytes and tumor cells. 
Fibrinogen cleavage products have been shown to act as chemoatractants for neutrophils, 
monocytes and fibroblasts. Specific chemoattractants include fibrinopeptide B (Bβ1+/-14) 
when released from fibrinogen by thrombin, and fibrinogen peptide (Bβ1+/-42). These two 
chemoatractants act comparatively to leukotriene B4 and platelet derived growth factor 
(PDGF) respectively [50]. 
Due to its inherent bioactivity, fibrinogen has been examined by tissue engineers in 
the past. Fibrinogen has been wet extruded with fibronectin into cables for use as a tissue 
scaffold, producing fibers 0.5mm in diameter [51]. Fibrinogen has been studied as a 
scaffold for chondrocytes in order to mimic cartilage [52, 53]. Fibronectin scaffolds doped 
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with fibrinogen have been shown to illicit a greater amount of cell migration compared to 
fibronectin scaffolds alone [54].  It is clear that fibrinogen certainly exhibits advantageous 
bioactivity in vitro.  
Further refinement of engineered fibrinogen constructs might offer a suitable 
scaffold for a variety of uses. Problems with several of the above applications of fibrinogen 
include large fiber size, and diminished structural strength when compared to many 
synthetic polymers. It has been reported that polyethelene glycol (PEG), a synthetic 
polymer, was modified with fibrinogen and used as scaffolds with a large degree of 
success.  This scaffold makes use of PEG molecules bound to a fibrinogen backbone so 
that the scaffolds retain the bioactivity of fibrinogen, yet also retain the mechanical 
properties, and cellular transparency of PEG. The use of a synthetic polymer and a natural 
polymer present an ideal solution for engineering a scaffold that is both bioactivley and 
mechanically sufficient respectively [55].  
Electrospinning has shown its ability to produce nanoscale, biocompatible fibers in 
the past [56, 57]. Fibrinogen for example has been successfully electrospun and 
characterized [58, 59].  Electrospun fibrinogen has very poor mechanical characteristics, 
especially when hydrated. It was suggested that mechanical properties of hydrated 
fibrinogen could be improved by chemical crosslinking of fibers. Glutaraldehyde exposure, 
a crosslinker that cross links R-group amines of lysine residues  to amino groups on other 
amino acids [60], was shown in vitro to have a negligible effect on mechanical properties 
of electrospun scaffolds [59]. Although electrospun fibrinogen offers benefits compared to 
extruded fibrinogen fibers and hydrogels, its mechanical properties fall short of ideal.  In 
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order to make use of fibrinogen as a scaffold, its mechanical properties need to be 
improved.  
Goals 
The goal of this research was to take two previously electrospun and characterized 
polymers and blend them, combining characteristics of both. Specifically, blended 
products should contain both the mechanical strength of polydioxanone, and the bioactivity 
of fibrinogen, in addition retaining fiber diameters and pore sizes that are similar to those 
of the ECM.  
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Materials and Methods 
 
Solution Preparation 
A stock solution of 120 mg/ml Fibrinogen (Sigma-Aldrich Chemical Company) was 
dissolved in HFP ( in 9 parts 1,1,1,3,3,3-hexaflouropropanol  (HFP; Sigma-Aldrich 
Chemical Company) and 1 part 10x minimal essential media and sodium bicarbonate)  at a 
concentration of 0.083 g/mL was made.  Polydioxanone stock solution was created by 
dissolving 100 mg/ml PDO (Ethicon)  in HFP. Since mixing the two solutions causes 
fibrinogen to precipitate, a novel coaxial electrospinning (Appendix 1) setup was used. The 
coaxial nozzle was set up so that PDO solution exited the core of the tip, while fibrinogen 
exited around the core. For each sample different ratios of PDO and FBG were used, but 
were kept in separate syringes to prevent precipitation, 4 mL of total solution was 
electrospun.  Each 4 ml sample differed by 10% volume of PDO and Fibrinogen (FBG). 
Samples included  both pure PDO and pure fibrinogen, for a total of eleven samples. 
Solutions were loaded by volume into separate Becton Dickinson syringes (3 ml or 5 ml). 
A table of volumes is shown below.  
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Ratio PDO:FBG Volume PDO (mL) Volume FBG (mL) 
100:0 4.0 0.0 
90:10 3.6 0.4 
80:20 3.2 0.8 
70:30 2.8 1.2 
60:40 2.4 1.6 
50:50 2.0 2.0 
40:60 1.6 2.4 
30:70 1.2 2.8 
20:80 0.8 3.2 
10:90 0.4 3.6 
0:100 0.0 4.0 
Table 1: Volumes of PDO and FBG used for each scaffold produced.  
Electrospinning 
In order to maintain a total overall solution deposition rate across samples, two 
separate KD Scientific syringe pumps were used. Using two pumps (KD Scientific Model 
100) allow for conservation of the overall solution deposition rate of 4 ml/hr.  An 18-gauge 
blunt needle was attached to the syringe. Tygon tubing with a 0.050” inner diameter and a 
0.090” outer diameter was placed over each blunt needle, and attached to the coaxial 
nozzle. The syringe containing fibrinogen was connected to the outer coaxial layer, while 
the polydioxanone was attached to the inner coaxial layer. The nozzle itself was positioned 
on top of  a stand and connected to the positive lead of a high voltage supply (Spellman 
CZE1000R; Spellman High Voltage Electronics Corp.).  A stainless steel, grounded target  
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(2.5 cm wide × 10.2 cm long × 0.3 cm thick) was rotating between 500 and 1000 
revolutions per minute (RPMs), and placed 15 cm from the nozzle.  
 
Uniaxial Tensile Testing. 
Tensile testing was performed to failure on both dry and hydrated samples (soaked 
in phosphate buffered saline (PBS) for 24 h). Samples were cut from an electrospun mat 
using a ‘dog-bone’ shaped punch (2.75 mm wide at its most narrow point and gage length 
of 7.5 mm). Thickness of samples were recorded, and samples were tested using a MTS 
Bionix 200 with a 50 N load cell (MTS Systems Corp.). An extension rate of 10.0  
mm/min was used. MTS software Testworks 4.0 was used to calculate and record elastic 
modulus, peak stress, and strain at failure. 
 
Scaffold Characterization 
Samples from each scaffold were taken and sputter coated in gold (Electron 
Microscope Sciences model 550) for scanning electron microscopy (Zeiss EVO 50 
Scanning Electron Microscope, SEM). Images at 2000x  were taken and analyzed by 
ImageTool 3.0 (Universiry of Texas Science Center in San Antonio, Shareware) in order to 
determine average fiber diameter and pore area. Calibration was performed using the scale 
bar on each SEM. Averages were determined by taking 60 measurements of both fiber 
diameter and pore area for each sample. 
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Fibroblast Cell Culture 
In order to determine cell proliferation, human dermal fibroblasts (HDF, ATCC CRL-
2522) were cultured  using 20 mL 1:1 DMEM/F12 (Gibco), 10 % heat inactivated Fetal 
Bovine Serum (Mediatech), 1% Pennacilin-Steptomycin (10,000 units/mL Penecylin G, 
10,000 μg/mL Streptomycin, Gibco)  media in 150 cm2 sterile tissue flasks. Cultures were 
stored in a 37°C humidified CO2  incubator and media refreshed every 2 days. Cells were 
subcultured in a ration of 1:3 using 0.25% Trypsin-EDTA (Gibco). This study used cells 
from passages 4-5.  
 
Scaffold Preparation  
Scaffolds were disinfected by soaking in ethanol for 10 minutes, followed by four 
successive 10 minute soaks in 1x Dubecco’s Phosphate Buffered Saline (MP Biomedicals). 
While still in PBS, scaffolds were punched with 10 mm2 biopsy punches (Picu Punch, 
Acuderm) and placed in 48 well cell culture cluster plates (Corning). Pyrex 10x10mm 
cloning rings (Corning) were then placed on top of the scaffolds to fix the position of the 
scaffold. 200 μl of PBS was added into the cloning ring, and the plates were incubated 
overnight in a 37°C humidified CO2 incubator. PBS was removed immediately prior to 
seeding.  
 
Cell Seeding 
HDFs were seeded 10,000 cells/well  in an initial volume of 50 μl of supplemented 
DMEM/F12 on PDO-Fibrinogen scaffolds (n = 5). After 45 minutes, an additional volume 
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of 150 μl was added, for a total of 200 μl. Cells were incubated on the scaffold for one and 
seven day periods. The media in the seven day culture was changed every two days.  
 
Cell Proliferation Assay 
In order to determine cell proliferation, a colorimetric MTS assay was used 
(Chemicon). In this assay, MTS reagent WST-1 (3-[4,5-dimethylthiazol-2-yl]-5-[3-
carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium)  reacts with mitochondrial 
cytochrome C in order to produce soluble formazan dye. The concentration of dye in 
solution can be quantified by measuring the absorbance at 420-480 nm. Scaffolds were 
removed from their incubation wells and placed in fresh wells. 200 μl of fresh media was 
added and 20 μl  MTS assay was added to each well. Plates were incubated for two hours. 
After incubation, plates were shaken on a Fisher Vortex Genie II shaker  for one minute. 
Aliquots from each scaffold were taken and pipetted into a 96-well plate.  The absorbance 
was measured at 450nm on a Molecular Devices SpectraMAX384 spectrophotometer.    
 
Histology 
Hematoxylin and Eosin (H&E) staining on 1 and 7 day culutres was preformed by 
Harris Histology Inc, Greenville NC. Microgaphs of sections were taken with a Nikon 
Eclipse TE300 light microscope at 20x magnification.  
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Statistics 
 All statistical analysis was performed using a one-way analysis of variance and  
Tukey-Kramer pairwise multiple comparison procedure (α = 0.05). Analysis was 
performed using JMP®IN 4.03, statistical software (SAS Institute, Inc.).  
 24 
 
 
Results 
Fiber Diameter and Pore Size  
 
SEM of different ratio dry scaffolds were taken at 2000x (Figure 5) and used to 
determine fiber diameter and pore size (Figure 6 and 7, respectively)  Fiber diameter 
ranged from a minimum of 0.3±0.1 μm  in 0:100 samples to 1.7±0.6 μm  in 100:0 samples. 
Average fiber diameter was seen to increase as the content of PDO increased. Fiber 
diameter of samples with higher PDO concentrations were significantly different than 
those with lower concentration.  
Pore size is shown to range from minimum 6.5±2.0 μm in 30:70 samples to 
14.0±2.0 μm in 100:0 samples. Pore size was shown to be statistically different in several 
samples. In general scaffolds containing higher concentrations of PDO were different than 
scaffolds containing lower concentrations of PDO. Samples with higher concentrations of 
PDO tended to have larger pore sizes.  
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Figure 5:  Figures A through K show SEM pictures taken at 2000x of dry PDO: FBG 
samples. Samples shown are A. 100:0, B. 90:10, C. 80:20, D. 70:30, E. 60:40, F. 50:50, G 
40:60, H. 30:70, I. 20:80, J. 10:90, K. 0:100. These samples were electrospun at 4mL/hr 
using 4mL of total solution at a potential of 25kv.  
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Figure 6: Relationship between PDO:FBG blends and fiber diameter. 
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Figure  7: Average pore sizes of various rations of PDO:FBG.    
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Mechanical Evaluation of Electrospun Scaffolds  
 
Modulus of elasticity calculations were performed on 11 groups, with 6 specimens 
from each group. The relationship between various concentrations of PDO and Fibrinogen 
are shown below in figure 8.  
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Figure 8 : Modulus of Elasticity  for varying concentrations by volume of both hydrated 
and dry PDO:FBG blends.  
 
Comparing dry samples of 100 PDO : 0 FBG to other samples showed significant 
differences between dry 50 PDO : 50 FBG samples, and dry 0 PDO : 100 FBG samples. 
Hydrated 100 PDO : 0 FBG differed from 30 PDO : 70 FBG, 20 PDO : 80 FBG,  and 10 
PDO : 90 FBG. Increasing modulus of elasticity seems to increase with increasing PDO 
concentrations in hydrated samples 
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 It is interesting to note that the dry modulus of elasticity is at its peak (28.0 MPa) in 
50 PDO 50 FBG samples, while the hydrated peak modulus is 13.6 MPa in 90 PDO 10 
FBG samples. The lowest modulus was observed in both wet and dry samples containing 
higher concentrations of fibrinogen.  
Peak stress was calculated from the same samples as above. Figure 9 shows the 
relationship between various concentrations of PDO and FBG and peak stress.  
It was determined that dry 100% PDO samples were different from all samples other than 
90:10 PDO:FBG samples. Hydrated samples of 100% PDO likewise differed from all other 
concentrations other than 90:10 PDO:FBG samples.  
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Figure 9: Graph of peak stress values for wet and hydrated ratios of PDO:FBG. 
 
Strain at break data is shown in figure 10. Again, comparisons of strain at break at 
various concentrations were performed using a Tukey analysis with an a priori level of 
significance set equal to 0.05.   Dry PDO samples were significantly different from all 
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other dry samples, while hydrated samples differed from all other samples except 10 PDO : 
90 FBG samples.   
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Figure 10: Relationship between concentrations of wet and hydrated PDO:FBG to strain at 
break.   
MTS Assay 
 In order to quantify cells using a MTS assay, a standard curve was constructed by 
taking absorbance of 2500, 5000, 10000, and 20000 cell/well standards after MTS 
treatment. A standard curve was constructed by plotting absorbance against number of 
cells per well (Figure 11). A linear regression was performed, and determine to have an 
equation of : 
Absorbance = 1x10-5 * Cell Number 
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It was determined that the linear regression had an R2 of 0.964 , indicating a relatively 
good fit.  
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Figure 11: Relationship between absorbance at 450nm and known  2500 , 5000, 10000, 
and 20000 cells/well. A trend line was used to determine the relationship between 
absorbance and cell concentration.  
 
 One day cell cultures were assayed for proliferation using a MTS assay. The results 
in Figure 12 show the relationship between PDO:FBG blends and cell proliferation. 
Scaffolds seeded with 10,000 cells were shown to range from a minimum average of 7,300 
cells on a pure PDO scaffold to a maximum average of 11,000 cells on a 90 FBG : 10 PDO 
scaffold. A Tukey-Kramer test was performed and no significant difference between 
polymer ratio and cell proliferation was observed.  
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Figure 12. Relationship between cell proliferation of 10,000 cells after 1 day, and various 
blends of PDO:FBG determined by MTS assay.   
 
Seven day cell cultures were assayed for proliferation in the same manner as one 
day cultures. The results in Figure 13 show the relationship between PDO:FBG blends and 
cell proliferation after 7 days. Samples of 90:10, 40:60, and 0:100 had n values of 2, 3 and 
3 respectively. All other samples had an n of 5. A wide variation of values can be noted. A 
Tukey-Kramer test was performed, and no significant difference between polymer ratio 
and cell proliferation was observed.  
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Figure 13. Relationship between cell proliferation of 10,000 cells after 7 days, and various 
blends of PDO:FBG determined by MTS assay.   
Histology 
 
Histological sections were taken after 1 and 7 days. Haematoxylin and Eosin 
(H&E) staining was used to identify cell bodies. In order to be considered a cell, an 
optically dense blue nuclei surrounded by a less dense region was needed for definitive 
identification.  Samples cultured for 1 day  are shown below in Figure 14. Cells on these 
scaffolds were scarce, and were only observed on the periphery of the scaffold. Day 7 
cultures of 90:10 to 10:90 (100:0 omitted due to processing error) appeared to have an 
increased number of cells. Most of the cells were found on the surfaces of the scaffold, 
however in scaffolds containing 40:60, 20:80, and 10:90 PDO:FBG ratios cells were found 
to have invaded the scaffolds.  
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Figure 14:  Figures A through I show 1 day histological sections stained with H & E 
staining of 100:0 to 10:90 scaffolds respectively. Samples shown are A. 100:0, B. 90:10, 
C. 80:20, D. 70:30, E. 60:40, F. 50:50, G 40:60, H. 30:70, I. 20:80, J. 10:90 .Scaffold were 
seeded with 10,000 human dermal fibroblasts. These samples were electrospun at 4mL/hr 
using 4mL of total solution at a potential of 25kv. Arrows indicate cells.   
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Figure 15: Figures A through I show 7 day histological sections stained with H & E 
staining of 90:10 to 10:90 scaffolds respectively. Samples shown are A. 90:10, B. 80:20, 
C. 70:30, D. 60:40, E. 50:50, F 40:60, G. 30:70, H. 20:80, I. 10:90. Scaffolds were seeded 
with 10,000 human dermal fibroblasts. These samples were electrospun at 4mL/hr using 
4mL of total solution at a potential of 25kv. Arrows indicate cells.   
G H
I
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Discussion 
 
As the need for non-allographic tissue grows, so will the demand for a suitable 
replacement. In order to be considered, such a replacement must mimic native tissues in 
several ways. First, the micro and nanoscale environment of the target tissue must be 
mimicked in the scaffold.  Specifically, scaffold fiber diameter and pore size must be 
similar to that of the ECM. Second, the replacement must have the mechanical strength of 
the target tissue. Finally, and most importantly, the scaffold must promote cell attachment 
and infiltration. Fulfilling these three criteria may make the scaffold more suitable for cell 
infiltration and proliferation. It is only when these requirements are met that the engineered 
scaffold might be considered as a suitable replacement. 
 
Scaffold Characterization 
 The first goal of this study was to successfully electrospin synthetic PDO and 
naturally derived fibrinogen. Upon addition of fibrinogen to a solution containing PDO and 
HFP, fibrinogen precipitation occurs. Precipitation prevents successful electrospinning. 
Methods to blend the two polymers without precipitation of fibrinogen were investigated. 
Keeping solutions of PDO and fibrinogen separate until mixing at the tip of a specially 
machined coaxial nozzle facilitated electrospinning. SEM analysis indicated that all 
concentrations of PDO and FBG resulted in successful deposition of  small diameter fibers 
on the mandrel. It was observed that only fibers were produced, and no sputtering took 
place.  
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 A correlation was observed between fiber diameter and PDO:FBG ratio (Figure 8).  
In samples with larger than 50% ratio of PDO:FBG, average fiber diameter was similar to 
that of pure PDO. Samples with PDO:FBG ratios below 50% PDO had fiber diameters 
more closely resembling that of pure fibrinogen. It is also important to note that the 
average fiber diameters for each 100:0 and 0:100 ratios are similar to their previously 
reported literature values [37, 59].  Some fibers produced were on a scale similar to that of 
the native ECM. Further customization of fiber diameter can be achieved by selecting 
certain ratios, but all still provide acceptable diameters for tissue engineering.  
Pore size was also compared to that of native tissue.  Average pore size ranged 
from a minimum average of 6.5 μm2 in 30:70 to a maximum average of 14.0 μm2 in 100:0 
ratios. These values all fell within the  50 nm2 to 300 μm2 range that has been reported to 
facilitate  infiltration [31].   
 
Mechanical Characterization  
 Polydioxanone has been reported to demonstrate strong mechanical characteristic, 
even after electrospinning [37]. This work intends to preserve the characteristics in all 
scaffold ratios. A trend in hydrated samples exists between PDO content and modulus. 
Higher PDO content increased elastic modulus. Samples with predominately PDO fibers, 
will maintain the characteristics of pure PDO. Hydrated blends ultimately mimic the 
scaffold in its target environment, therefore trends in hydrated samples are more pertinent 
to this study.  
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Strain at break was significantly larger in 100:0 and 90:10  for both dry and 
hydrated samples. These samples, containing mostly PDO, exhibited stain at break 
properties closely associated to pure electrospun PDO. All hydrated samples containing 
fibrinogen had higher strain at break than their dry counterparts.  
Peak stress of 100:0 and 90:10 dry and hydrated samples was significantly different 
compared to those of the other samples. Any further decrease of PDO or increase in 
fibrinogen after this point yields a significantly diminished peak stress. Although peak 
stress decreases, both dry and wet samples with PDO:FBG ratios above 10:90 exhibited 
superior peak stress values compared to  0.2 MPa reported for human ureter[61]. The 
roughly ten-fold increase in peak stress values is significant. It is important that the 
scaffold retain sufficient stress values as remodeling and degradation take place. 
Mechanical testing of these scaffolds served to elucidate the effect of incorporation 
of fibrinogen into polydioxnaone scaffolds. Inclusion of fibrinogen significantly altered 
mechanical properties compared to those of pure PDO. Fibrinogen incorporation did not 
alter the scaffolds to the point where they were made weak. In fact, samples with ratios of 
PDO:FBG over 10:90 proved mechanically superior to that of the human ureter. It is 
important to note that scaffolds containing pure fibrinogen did not have enough structural 
integrity to allow for mechanical testing after hydration.  
 
Cell Proliferation Assays 
 The results of the one day MTS assay indicated that roughly the same number of 
seeded cells remained viable on the scaffold after one day. Surprisingly, the seven day 
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assay showed a high degree of variability with several samples showing lower than 
expected cell counts. Although it is difficult to draw finite conclusions,  data from 20:80, 
10:90, and 0:100 samples on average demonstrated a slight increase in average number of 
cells despite a high degree of variability.  
It is suspected that both the variability and low cell counts are due to the nature of 
the scaffold and MTS assay. The MTS assay involves the conversion of MTS reagent to 
soluble formazan dye, which absorbs light around 450nm. Not only must the MTS reagent 
penetrate into the scaffold, but once converted to formazan, it must be homogenously 
redistributed throughout the culture media. Although samples were agitated prior to 
testing, complete redistribution of formazan may not have occurred. In addition, it is 
possible that the dye simply become bound and stuck to some of the scaffolds. Based on 
this contention, it is suggested that future studies involve altered protocols, or alternatives 
to the MTS assay.  
Histology  
H & E staining was performed on 1 and 7 day samples. After culture for one day, 
all ratios of PDO:FBG showed fibroblasts on their surface. Immediate infiltration was not 
assumed, and we hypothesized that cells would be attached to the surface of the scaffolds. 
We also hypothesized that over a seven day incubation, cells would migrate through the 
thickness of the scaffold. PDO:FBG ratios of  40:60, 20:80, and 10:90 all were found to 
have cells that infiltrated, while other scaffolds had cells on their surface. It is interesting to 
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note that scaffolds in which infiltration occurred all had larger amounts of fibrinogen than 
PDO. Therefore a threshold ratio might exist that promotes infiltration.  
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Conclusions 
 
 The goals of this study were to blend two previously electrospun polymers, PDO 
and fibrinogen and to produce a blended product that retained both the mechanical strength 
of PDO and the cell growth promoting characteristics of pure fibrinogen. The 
incorporation of PDO with fibrinogen increased the overall mechanical strength compared 
to the strength of only fibrinogen. Additionally, fiber diameter and pore size were 
characterized. Fiber diameter and pore size values remained within limits compared to 
reported values of the ECM.   The ability of these scaffolds to facilitate attachment and 
proliferation was determined with an MTS assay and observed qualitatively through 
histological staining. Both assessments showed that scaffolds supported cell growth. 
Histological staining showed three ratios of PDO:FBG that facilitated cell infiltration. 
These three ratios of PDO:FBG, 40:60 , 20:80, and 10:90, all supported cell infiltration 
after a 7 day culture. 
 The applications of a scaffold that is both bioactive and structurally similar to 
native tissue are numerous. Specifically, these scaffolds were intended for use in urological 
applications. Ureter and urethral stricture, due to obstruction or congenital abnormalities 
respectively, are pervasive. Current treatments are not sufficient, and the development of a 
new tissue scaffold might aide future work.  
 Although this study successfully indicated cell infiltration into blended scaffolds, it 
is not without flaw. The MTS assay proved imprecise with 7 day culture samples. Cell 
infiltration into the scaffold was assumed, and penetration of MTS reagent may have been 
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impeded by the scaffold itself. We also suspected that upon shipping samples for histology, 
some detachment of cells may occur.  
 Future work must be conducted in order to prove further the effectiveness of 
scaffolds made from PDO and fibrinogen. Smooth muscle cells, and epithelial cells of the 
ureter and urethra must be used to determine their proliferation and infiltration into these 
scaffolds. Longer term studies of the degradation of these scaffolds must also be 
conducted. We have hypothesized that cleaving fibrinogen to fibrin via thrombin might 
expose more bioactive domains. Crosslinking fibrin via factor XIII might also serve to 
benefit cellular response. Finally, the effectiveness of these scaffolds in vivo must be 
considered. 
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APPENDIX A 
 
 
 
 
Coaxial Electrospinning Nozzle.  Left figure shows the side view of the nozzle. The two 
labeled inlets are for PDO and fibrinogen. The right figure shows the coaxial outlet of the 
nozzle.  
 
 
 Fibrinogen inlet 
PDO 
inlet 
Fibrinogen 
outlet  
PDO 
outlet 
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APPENDIX B 
 
 
 100:0 80:20 90:10 60:40 50:50 70:30 20:80 40:60 10:90 30:70 0:100
100:0  * * * * * * * * * * 
80:20 *     * * * * * * 
90:10 *     * * * * * * 
60:40 *     * * * * * * 
50:50 *      * * * * * 
70:30 *  * *    * * * * 
20:80 * * * * *      * 
40:60 * * * * * *     * 
10:90 * * * * * *      
30:70 * * * * * *      
0:100 * * * * * * * *    
Table of statistical differences between fiber diameter and PDO:FBG ratios. Diameters 
were determined using ImageTool. Asterisks (*) indicate significant difference.  
 
 100:0 60:40 90:10 80:20 70:30 50:50 40:60 0:100 10:90 30:70 20:80
100:0  * * * * * * * * * * 
60:40   * * * * * * * * * 
90:10    * * * * * * * * 
80:20     * * * * * * * 
70:30      * * * * * * 
50:50       * * * * * 
40:60        * * * * 
0:100         * * * 
10:90          * * 
30:70           * 
20:80            
 
Table of statistical difference between pore size and PDO:FBG rations. Pore size was 
determined using ImageTool. Asterisks indicate significant difference. 
 
 
 
 
 
 
100:0 
dry 
90:10 
wet 
100:0 
wet 
90:10 
dry 
80:20 
Dry 
60:40 
Wet 
50:50 
Wet 
60:40 
Dry 
80:20 
Wet 
50:50 
Dry 
70:30 
Wet 
70:30 
Dry 
40:60 
Wet 
30:70 
Wet 
40:60 
Dry 
20:80 
Dry 
0:100 
Dry 
20:80 
Dry 
10:90 
Wet 
30:70 
Wet 
100:0 
Dry     * * * * * * * * * * * * * * * * 
90:10 
Wet     * * * * * * * * * * * * * * * * 
100:0 
wet     * * * * * * * * * * * * * * * * 
51 
90:10 
dry     * * * * * * * * * * * * * * * * 
80:20 
Dry * * * *            * * * * * 
60:40 
Wet * * * *             * * * * 
50:50 
Dry * * * *                 
60:40 
Wet * * * *                 
80:20 
dry * * * *                 
50:50 
dry * * * *                 
70:30 
wet * * * *                 
70:30 
dry * * * *                 
40:60 
wet * * * *                 
30:70 
dry * * * *                 
40:60 
dry * * * *                 
20:80 
dry * * * * *                
0:100 
dry * * * * * *               
20:80 
wet * * * * * *               
10:90 
dry * * * * * *               
30:70 
wet * * * * * *               
10:90 
wet * * * * * * * * * *           
 
.  
Table of statistical difference between preak stress and PDO:FBG rations. Peak stress was 
determined using a MTS Bionix 200 tensile tester.  Asterisks indicate significant 
difference. 
 
 
50:50 
dry 
60:40 
dry 
90:10 
dry 
80:20 
dry 
40:60 
dry 
100:0 
dry 
70:30 
dry 
30:70 
dry 
100:0 
wet 
90:10 
wet 
20:80 
dry 
10:90 
dry 
80:20 
wet 
60:40 
wet 
50:50 
wet 
0:100 
dry 
70:30 
wet 
40:60 
wet 
30:70 
wet 
20:80 
wet 
50:50 
dry     *  * * * * * * * * * * * * * * 
60:40 
dry        * * * * * * * * * * * * * 
90:10 
dry          * * * * * * * * * * * 
80:20 
dry          * * * * * * * * * * * 
40:60 
dry *            * * * * * * * * 
100:0 
dry *              * * * * * * 
70:30 
dry *                 * * * 
30:70 
dry * *                * * * 
100:0 
wet * *                 * * 
90:10 
wet * * * *                 
20:80 
dry * * * *                 
10:90 
dry * * * *                 
80:20 
wet * * * * *                
60:40 
wet * * * * *                
50:50 
wet * * * * * *               
0:100 
dry * * * * * *               
70:30 
wet * * * * * * *              
40:60 
wet * * * * * * * *             
30:70 
wet * * * * * * * * *            
20:80 
wet * * * * * * * * *            
52 
10:90 
wet * * * * * * * * *            
 
Table of statistical difference between elastic modulus and PDO:FBG rations. Peak stress 
was determined using a MTS Bionix 200 tensile tester.  Asterisks indicate significant 
difference. 
 
 
 
 
100:0 
Dry 
100:0 
Wet 
90:10 
wet 
10:90 
wet 
40:60 
wet 
20:80 
 wet 
30:70 
wet 
90:10  
dry 
60:40 
 wet 
50:50 
 Wet 
80:20  
dry 
70:30 
 wet 
80:20 
 dry 
70:30 
 dru 
20:80  
dry 
0:100 
 dry 
50:50 
 dry 
60:40 
 dry 
10:90 
 dry 
40:60 
 dry 
100:0 
Dry   * * * * * * * * * * * * * * * * * * 
100:0 
Wet     * * * * * * * * * * * * * * * * 
90:10 
wet *           * * * * * * * * * 
10:90 
wet * *          * * * * * * * * * 
40:60 
wet * *           * * * * * * * * 
20:80 
wet * *           * * * * * * * * 
30:70 
wet * *           * * * * * * * * 
90:10 
dry * *           * * * * * * * * 
60:40 
wet * *            * * * * * * * 
50:50 
wet * *            * * * * * * * 
80:20 
dry * *            * * * * * * * 
70:30 
wet * * * *             * * * * 
80:20 
dry * * * * * * * *             
70:30 
dru * * * * * * * * * * *          
20:80 
dry * * * * * * * * * * *          
0:100 
dry * * * * * * * * * * *          
50:50 
dry * * * * * * * * * * * *         
60:40 
dry * * * * * * * * * * * *         
10:90 
dry * * * * * * * * * * * *         
40:60 
dry * * * * * * * * * * * *         
30:70 
dry * * * * * * * * * * * *         
 
Table of statistical difference between elastic modulus and PDO:FBG rations. Peak stress 
was determined using a MTS Bionix 200 tensile tester.  Asterisks indicate significant 
difference. 
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